Maryann Selfe on Wealth Office | Wealth Office
财富办公室

Guests

Maryann Selfe

Maryann Selfe

Author of The Billion Dollar Blindspot and healthcare investor

Biography

Maryann Selfe is an investment strategist, healthcare investor and the author of The Billion Dollar Blindspot: Why Women's Health Is the Investment Opportunity of Our Time. She is founder and Chief Investment Officer of Calabar Capital, which invests in women's health and healthcare technology, and founder and president of FemmeHealth Alliance, an independent Swiss non-profit.

Career in institutional finance

Selfe spent more than 20 years in institutional investment management, private banking and wealth management, much of it at Credit Suisse, which later became part of UBS. In that time she invested capital in public and private markets, built investment portfolios and structured cross-border investment solutions. Her experience includes portfolio construction, investment risk and capital allocation; she has reviewed more than 1,000 fund managers and worked on investment risk oversight covering more than US$100 billion.

Calabar Capital and FemmeHealth Alliance

Selfe founded Calabar Capital as a healthcare-focused investment and advisory platform. It invests in women's health and healthcare technology through specialist venture funds and direct co-investments, and she advises clients who want to deploy capital in healthcare. She also founded FemmeHealth Alliance, a convening platform that connects investors, fund managers, healthcare leaders and researchers with the aim of directing capital towards women's health innovation.

Her interest in the field began with her own health. She has uterine fibroids, a condition she says affects up to 80% of women by the age of 50, and she began to question why better treatments did not exist.

The Billion Dollar Blindspot

The Billion Dollar Blindspot grew out of Selfe's research into why healthcare needs affecting half the population were largely absent from mainstream investment frameworks. The book argues that medicine historically treated male biology as the default human model, and traces how a persistent gap in data about women's health has left the sector underpriced by investors. She publishes a newsletter under the same name, writes for CEOWORLD magazine on healthcare innovation, demographic change and investment, and has coined the term "The Precision Premium". She has spoken at events including the Institutional Investor DACH Summit, the Zurich Fund Forum, the Shanghai Global Women's Health Capital Summit and the SIP-BILANZ Health & Longevity Conference.

On Wealth Office

Selfe spoke to Michael Macfarlane in the Wealth Office episode "The Billion Dollar Blindspot in Women's Healthcare". She argued that healthcare is being repriced in real time, citing growth in health tech and women's health funding, and explained how women came to be excluded from clinical trials after the thalidomide scandal and why drugs such as Ambien later had to be re-dosed for women. She described a self-reinforcing cycle in which missing data leads to weak reimbursement, a weak commercial case and little capital. She identified three converging forces: 1.2 billion women in menopause by 2030, longer lives bringing conditions such as dementia and autoimmune disease into view, and women gaining control of capital. She made the case that long-duration family capital, particularly from Asia, is well suited to these opportunities, and said she prefers to call the field health for all.

On Wealth Office

The Billion Dollar Blindspot in Women's Healthcare

Maryann Selfe, author of The Billion Dollar Blindspot, explains how a data gap left women's health underpriced, and why long-duration private capital is well placed for the correction.

Insights drawing on Selfe